|
KMID : 0869620130300030194
|
|
Journal of Korean Society of Hospital Pharmacists
2013 Volume.30 No. 3 p.194 ~ p.201
|
|
|
Evaluation of Oral Vancomycin Use for the Treatment of Clostridium Difficile-Associated Disease and Risk Factor Analysis of Treatment Failure
|
|
Choi Yoo-Jung
Cho Yoon-Sook
Lee Hye-Sook
Kim Hyang-Suk
Lee Ju-Yeun
|
|
|
Abstract
|
|
|
The number of Clostridium difficile-associated disease(CDAD) event and mortality of CDAD have been increasing due to the emergence of mutant BI/NAP1/027 which can produce C.difficile toxin about 10~20 times more than the existing C.difficile.
According to the clinical practice guideline from Society for Healthcare Epidemiology of America (SHEA) and the Society for Healthcare Epidemiology of America (SHEA), prescribing oral metron-idazole or oral vancomycin for 10~14 days depending on clinical status is recommended for adult Clostridium difficile infection. This study aimed to evaluate oral vancomycin use for the treatment of CDAD and analyze the risk factor for treatment failure.
Clinical data of CDAD patient who treated with oral vancomycin from April 2008 to August 2010
were retrospectively reviewed. We classified patients into two groups, depending on the clinical outcome on the 10th day and identified risk factor of treatment failure. Seventy two patients were included in this analysis. Forty eight patients (66.7%) and sixty one patients (84.7%) recovered from CDAD on the 10th day of treatment and by 28th days from the start of oral vancomycin. Patients with high disease severity score and patients who defecate more than six times a day at the time of treatment start are more likely to experience treatment failure.
|
|
|
KEYWORD
|
|
|
Clostridium difficile-associated disease, Oral vancomycin, Oral metronidazole
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|